Biotech company aims for sale before next development phase
On an early experimental stage, the Danish biotech company Rhovacs has developed a cancer vaccine that successfully mobilizes the patient’s own immune system against cancer. The company hopes that the positive data will result in a sale of the firm.
BY MIKKEL AABENHUS HEMMINGSEN
So far, seven out of eight patients have responded to the cancer vaccine candidate RV001in a clinical phase I/II trial.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
